Orchestra BioMed Holdings, Inc. (OBIO)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1814114 · fiscal year ends in Dec
Closing price $5.92 on 30 Oct 2026; 52-week range $3.49 to $6.36.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $32.0M
- Revenue growth
- 986.1%
- Net income, last twelve months
- -$59.0M
- Gross margin
- 99.5%
- Operating margin
- -181.4%
- Net margin
- -184.6%
- Free cash flow
- -$59.1M
- Return on equity
- -305.5%
- Market value
- $355.8M
- Cash
- $20.5M
- Debt
- $34.8M
- Debt to equity
- 1.80
- Shares outstanding
- 60.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $33.5M | -$51.8M | -$52.7M | -$1.11 | -$49.5M | 10-K filed 12 Mar 2026 |
| FY2024 | 31 Dec 2024 | $2.6M | -$64.3M | -$61.0M | -$1.66 | -$50.8M | 10-K filed 31 Mar 2025 |
| FY2023 | 31 Dec 2023 | $2.8M | -$51.5M | -$49.1M | -$1.48 | -$46.2M | 10-K filed 27 Mar 2024 |
| FY2022 | 31 Dec 2022 | $3.5M | -$32.7M | -$33.6M | -$2.24 | -$29.9M | 10-K filed 27 Mar 2024 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $88.0K | -$23.8M | -$0.38 |
| Q1 FY2026 | 31 Mar 2026 | $110.0K | -$20.7M | -$0.33 |
| Q4 FY2025 | 31 Dec 2025 | $30.9M | $6.2M | $0.28 |
| Q3 FY2025 | 30 Sep 2025 | $861.0K | -$20.8M | -$0.40 |
| Q2 FY2025 | 30 Jun 2025 | $836.0K | -$19.4M | -$0.50 |
| Q1 FY2025 | 31 Mar 2025 | $868.0K | -$18.8M | -$0.49 |
| Q4 FY2024 | 31 Dec 2024 | $253.0K | -$16.2M | -$0.42 |
| Q3 FY2024 | 30 Sep 2024 | $987.0K | -$15.4M | -$0.41 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Partnership revenue | $32.9M | 98.2% |
| Product revenue | $611.0K | 1.8% |
Company events
The newest 8-K filings of 45 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 1 Oct 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 8 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 23 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 13 Feb 2026 | 8-K | Leadership change | 5.02 |
| 12 Jan 2026 | 8-K | Other events | 8.01, 9.01 |
| 13 Nov 2025 | 8-K | Investor update | 7.01, 9.01 |
| 30 Oct 2025 | 8-K | Investor update | 7.01, 9.01 |
| 28 Oct 2025 | 8-K | Material agreement, Agreement ended, Share sale, Investor update, Other events | 1.01, 1.02, 3.02, 7.01, 8.01, 9.01 |
| 4 Aug 2025 | 8-K | Material agreement, Investor update, Other events | 1.01, 7.01, 8.01, 9.01 |
| 31 Jul 2025 | 8-K | Material agreement, New debt, Share sale, Investor update, Other events | 1.01, 2.03, 3.02, 7.01, 8.01, 9.01 |
| 24 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 29 Apr 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 147 held.
| Filed | Form | Period |
|---|---|---|
| 1 Oct 2026 | 8-K | 1 Oct 2026 |
| 8 Sep 2026 | 8-K | 8 Sep 2026 |
| 10 Aug 2026 | 10-Q | 30 Jun 2026 |
| 23 Jun 2026 | 8-K | 23 Jun 2026 |
| 23 Jun 2026 | S-8 | – |
| 16 Jun 2026 | DEFA14A | – |
| 12 May 2026 | 10-Q | 31 Mar 2026 |
| 29 Apr 2026 | ARS | 31 Dec 2025 |
| 29 Apr 2026 | DEFA14A | – |
| 29 Apr 2026 | DEF 14A | 23 Jun 2026 |
| 12 Mar 2026 | 10-K | 31 Dec 2025 |
| 13 Feb 2026 | 8-K | 12 Feb 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 1 Oct 2026 | Sherman Darren, See Remarks | Sale under a trading plan | 15,000 | $6.36 | $95.4K | 1,119,402 | 2 Oct 2026 |
| 3 Sep 2026 | Hochman David P, See Remarks | Purchase | 10,000 | $4.79 | $47.9K | 1,070,746 | 8 Sep 2026 |
| 1 Sep 2026 | Sherman Darren, See Remarks | Sale under a trading plan | 15,000 | $4.94 | $74.1K | 1,134,402 | 2 Sep 2026 |
| 26 Aug 2026 | Sherman Darren, See Remarks | Purchase | 2,000 | $5.33 | $10.7K | 2,000 | 28 Aug 2026 |
| 3 Aug 2026 | Sherman Darren, See Remarks | Sale under a trading plan | 15,000 | $4.09 | $61.4K | 1,154,327 | 4 Aug 2026 |
| 1 Jul 2026 | Sherman Darren, See Remarks | Sale under a trading plan | 15,000 | $4.27 | $64.0K | 1,169,327 | 2 Jul 2026 |
| 1 Jun 2026 | Hochman David P, See Remarks | Purchase | 5,000 | $3.83 | $19.1K | 1,064,029 | 2 Jun 2026 |
| 1 Jun 2026 | Sherman Darren, See Remarks | Sale under a trading plan | 15,000 | $3.87 | $58.0K | 1,184,327 | 2 Jun 2026 |
| 18 May 2026 | Aryeh Jason, Director | Purchase | 665 | $3.75 | $2.5K | 118,118 | 20 May 2026 |
| 15 May 2026 | Aryeh Jason, Director | Purchase | 8,971 | $3.90 | $35.0K | 117,453 | 19 May 2026 |
| 15 May 2026 | Hochman David P, See Remarks | Purchase | 5,000 | $3.77 | $18.9K | 1,059,029 | 19 May 2026 |
| 14 May 2026 | Fain Eric S, Director | Purchase | 20,000 | $4.13 | $82.6K | 91,709 | 18 May 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 1 Oct 2026 | Sherman Darren, Officer, Director | 15,000 | $94.0K | 1 Oct 2026 |
| 1 Sep 2026 | Sherman Darren, Officer, Director | 15,000 | $75.3K | 1 Sep 2026 |
| 3 Aug 2026 | Sherman Darren, Officer, Director | 15,000 | $61.3K | 3 Aug 2026 |
| 1 Jul 2026 | Sherman Darren, Officer, Director | 15,000 | $64.8K | 1 Jul 2026 |
| 1 Jun 2026 | Sherman Darren, Officer, Director | 15,000 | $58.0K | 1 Jun 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 29 Apr 2026 | RTW Investments, LP | 13D amended | 19.2% | 11.9M |
| 27 Feb 2026 | Medtronic plc | 13G amended | 17.8% | 10.1M |
| 25 Feb 2026 | RTW Investments, LP | 13D amended | 19.7% | 11.9M |
| 19 Nov 2025 | Tasso Partners, LLC | 13G | 5.5% | 3.1M |
| 14 Nov 2025 | Perceptive Advisors LLC | 13G amended | 9.99% | 5.7M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.6M | +0.23% | 9.7 |
| 30 Sep 2026 | 2.5M | +7.36% | 6.98 |
| 15 Sep 2026 | 2.4M | -3.58% | 6.57 |
| 31 Aug 2026 | 2.5M | +3.22% | 5.82 |
| 14 Aug 2026 | 2.4M | -1.72% | 13.12 |
| 31 Jul 2026 | 2.4M | -6.31% | 13.37 |
| 15 Jul 2026 | 2.6M | +16.45% | 10.86 |
| 30 Jun 2026 | 2.2M | +79.49% | 2.71 |
Funds that hold it
From each fund's latest Form 13F.
90 funds held it at 30 Jun 2026: 47 added and 15 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| RTW Investments, LP | 9,556,063 | $41.2M | +1,250,000 |
| Perceptive Advisors LLC | 5,037,906 | $21.7M | 0 |
| BlackRock, Inc. | 2,510,387 | $10.8M | +1,874,673 |
| Vanguard Capital Management LLC | 2,022,916 | $8.7M | -181,403 |
| Geode Capital Management, LLC | 1,007,908 | $4.4M | +522,416 |
| Alyeska Investment Group, L.P. | 1,000,000 | $4.3M | 0 |
| Propel Bio Management, LLC | 896,701 | $3.9M | 0 |
| UBS AM, a distinct business unit of UBS Asset Management Americas LLC | 642,154 | $2.8M | +642,154 |
| State Street Corp. | 516,050 | $2.2M | +346,640 |
| Rice Hall James & Associates, LLC | 424,000 | $1.8M | +404,999 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B